Onconova Therapeutics Announces Additional Clinical Data Demonstrating Rigosertib’s Monotherapy Activity In RDEB-Associated Squamous Cell Carcinoma

Onconova Therapeutics, Inc. announced that the second of two evaluable participants in an investigator-initiated Phase II program evaluating rigosertib monotherapy in advanced squamous cell carcinoma complicating recessive dystrophic epidermolysis bullosa (RDEB-associated SCC) achieved a complete response of all cancerous skin lesions following 4 treatment cycles and remains on oral rigosertib.